Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol conjugation

Journal of Biological Chemistry

Volumn 289, Issue 50, 2014, Pages 35015-35028

  Lacek, Krzysztof ^a,b   Urbanowicz, Richard A ^c   Troise, Fulvia ^a   De Lorenzo, Claudia ^a,d   Severino, Valeria ^e   Di Maro, Antimo ^e   Tarr, Alexander W ^c   Ferrara, Francesca ^f   Ploss, Alexander ^g   Temperton, Nigel ^f   Ball, Jonathan K ^c   Nicosia, Alfredo ^a,d   Cortese, Riccardo ^a   Pessi, Antonello ^a,h  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF GDA SK   (Poland)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f UNIVERSITY OF KENT   (United Kingdom)

^g PRINCETON UNIVERSITY   (United States)

^h JV Bio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; CHOLESTEROL; DISEASES; EPITOPES; MEMBRANES; VIRUSES;

AFFINITY MATURATION; ANTIVIRAL ACTIVITIES; FUSION PROTEINS; HIGH AFFINITY; MEMBRANE AFFINITY; NEUTRALIZING ANTIBODIES; TWO-STEP MECHANISMS; VIRUS STRAINS;

ANTIBODIES;

MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; CHOLESTEROL; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIVIRAL ACTIVITY; ARTICLE; CHOLESTEROL CONJUGATION; CONJUGATION; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID RAFT; NONHUMAN; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; CELL MEMBRANE; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 2;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL MEMBRANE; CHOLESTEROL; HEK293 CELLS; HIV ANTIBODIES; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 84918544609     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.591826     Document Type: Article

References (53)

1. Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., and Katinger, H. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67, 6642-6647
2. Salzwedel, K., West, J. T., and Hunter, E. (1999) A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73, 2469-2480
3. Cardoso, R. M. F., Zwick, M. B., Stanfield, R. L., Kunert, R., Binley, J. M., Katinger, H., Burton, D. R., and Wilson, I. A. (2005) Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22, 163-173
4. Ofek, G., Tang, M., Sambor, A., Katinger, H., Mascola, J. R., Wyatt, R., and Kwong, P. D. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78, 10724-10737
5. Ofek, G., McKee, K., Yang, Y., Yang, Z. Y., Skinner, J., Guenaga, F. J., Wyatt, R., Zwick, M. B., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010) Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region. J. Virol. 84, 2955-2962
6. Alam, S. M., Morelli, M., Dennison, S. M., Liao, H. X., Zhang, R., Xia, S. M., Rits-Volloch, S., Sun, L., Harrison, S. C., Haynes, B. F., and Chen, B. (2009) Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U.S.A. 106, 20234-20239
7. Xu, H., Song, L., Kim, M., Holmes, M. A., Kraft, Z., Sellhorn, G., Reinherz, E. L., Stamatatos, L., and Strong, R. K. (2010) Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity. J. Virol. 84, 1076-1088
8. Julien, J. P., Huarte, N., Maeso, R., Taneva, S. G., Cunningham, A., Nieva, J. L., and Pai, E. F. (2010) Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 84, 4136-4147
9. Brügger, B., Glass, B., Haberkant, P., Leibrecht, I., Wieland, F. T., and Kräusslich, H. G. (2006) The HIV lipidome: a raft with an unusual composition. Proc. Natl. Acad. Sci. U.S.A. 103, 2641-2646
10. Eckert, D. M., and Kim, P. S. (2001) Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70, 777-810
11. Muñoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., and Blumenthal, R. (1998) Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140, 315-323
12. Kim, M., Sun, Z.-Y. J., Rand, K. D., Shi, X., Song, L., Cheng, Y., Fahmy, A. F., Majumdar, S., Ofek, G., Yang, Y., Kwong, P. D., Wang, J.-H., Engen, J. R., Wagner, G., and Reinherz, E. L. (2011) Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat. Struct. Mol. Biol. 18, 1235-1243
13. Guenaga, J., and Wyatt, R. T. (2012) Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function. PLoS Pathog. 8, e1002806
14. Ono, A., and Freed, E. O. (2005) Role of lipid rafts in virus replication. Adv. Virus Res. 64, 311-358
15. Bentz, J. (2000) Membrane fusion mediated by coiled coils: a hypothesis. Biophys. J. 78, 886-900
16. Bentz, J. (2000) Minimal aggregate size and minimal fusion unit for the first fusion pore of influenza hemagglutinin-mediated membrane fusion. Biophys. J. 78, 227-245
17. Chernomordik, L. V., Frolov, V. A., Leikina, E., Bronk, P., and Zimmerberg, J. (1998) The pathway of membrane fusion catalyzed by influenza hemagglutinin: restriction of lipids, hemifusion, and lipidic fusion pore formation. J. Cell Biol. 140, 1369-1382
18. Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., Liu, F., Miller, C., Tota, L. M., Zhou, G., Zhang, X., Sountis, M. M., Santoprete, A., Capito', E., Chicchi, G. G., Thornberry, N., Bianchi, E., Pessi, A., Marsh, D. J., and SinhaRoy, R. (2009) Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 58, 2258-2266
19. Dwyer, J. J., Wilson, K. L., Davison, D. K., Freel, S. A., Seedorff, J. E., Wring, S. A., Tvermoes, N. A., Matthews, T. J., Greenberg, M. L., and Delmedico, M. K. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc. Natl. Acad. Sci. U.S.A. 104, 12772-12777
20. Welsch, J. C., Talekar, A., Mathieu, C., Pessi, A., Moscona, A., Horvat, B., and Porotto, M. (2013) Fatal measles virus infection prevented by brain-penetrant fusion inhibitors. J. Virol. 87, 13785-13794
21. Ingallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y.-J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T. J., Moore, J. P., Miller, M. D., and Pessi, A. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U.S.A. 106, 5801-5806
22. Porotto, M., Yokoyama, C. C., Palermo, L. M., Mungall, B., Aljofan, M., Cortese, R., Pessi, A., and Moscona, A. (2010) Viral entry inhibitors targeted to the membrane site of action. J. Virol. 84, 6760-6768
23. Porotto, M., Rockx, B., Yokoyama, C. C., Talekar, A., Devito, I., Palermo, L. M., Liu, J., Cortese, R., Lu, M., Feldmann, H., Pessi, A., and Moscona, A. (2010) Inhibition of Nipah virus infection in vivo: targeting an early stage of paramyxovirus fusion activation during viral entry. PLoS Pathog. 6, e1001168
24. Lee, K. K., Pessi, A., Gui, L., Santoprete, A., Talekar, A., Moscona, A., and Porotto, M. (2011) Capturing a fusion intermediate of influenza hemagglutinin with a cholesterol-conjugated peptide, a new antiviral strategy for influenza virus. J. Biol. Chem. 286, 42141-42149
25. Pessi, A., Langella, A., Capitò, E., Ghezzi, S., Vicenzi, E., Poli, G., Ketas, T., Mathieu, C., Cortese, R., Horvat, B., Moscona, A., and Porotto, M. (2012) A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity. PLoS One 7, e36833
26. Francis, J. N., Redman, J. S., Eckert, D. M., and Kay, M. S. (2012) Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry. Bioconjug Chem. 23, 1252-1258
27. Ashkenazi, A., Viard, M., Unger, L., Blumenthal, R., and Shai, Y. (2012) Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1. FASEB J. 26, 4628-4636
28. Teruya, K., Nishizawa, K., and Doh-ura, K. (2010) Semisynthesis of a protein with cholesterol at the C-terminal, targeted to the cell membrane of live cells. Protein J. 29, 493-500
29. Persic, L., Roberts, A., Wilton, J., Cattaneo, A., Bradbury, A., and Hoogenboom, H. R. (1997) An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187, 9-18
30. Sharpless, N. E., and Flavin, M. (1966) The reactions of amines and amino acids with maleimides: structure of the reaction products deduced from infrared and nuclear magnetic resonance spectroscopy. Biochemistry 5, 2963-2971
31. a values in proteins. Proteins 69, 75-82
32. Chou, T. C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681
33. Junutula, J. R., Raab, H., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., Lu, Y., Meng, Y. G., Ng, C., Yang, J., Lee, C. C., Duenas, E., Gorrell, J., Katta, V., Kim, A., McDorman, K., Flagella, K., Venook, R., Ross, S., Spencer, S. D., Lee Wong, W., Lowman, H. B., Vandlen, R., Sliwkowski, M. X., Scheller, R. H., Polakis, P., and Mallet, W. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925-932
34. Stimmel, J. B., Merrill, B. M., Kuyper, L. F., Moxham, C. P., Hutchins, J. T., Fling, M. E., and Kull, F. C., Jr. (2000) Site-specific conjugation on serine → cysteine variant monoclonal antibodies. J. Biol. Chem. 275, 30445-30450
35. Voynov, V., Chennamsetty, N., Kayser, V., Wallny, H. J., Helk, B., and Trout, B. L. (2010) Design and application of antibody cysteine variants. Bioconjug. Chem. 21, 385-392
36. Junutula, J. R., Bhakta, S., Raab, H., Ervin, K. E., Eigenbrot, C., Vandlen, R., Scheller, R. H., and Lowman, H. B. (2008) Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332, 41-52
37. Kwong, P. D., and Wilson, I. A. (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat. Immunol. 10, 573-578
38. Miller, M. D., Geleziunas, R., Bianchi, E., Lennard, S., Hrin, R., Zhang, H., Lu, M., An, Z., Ingallinella, P., Finotto, M., Mattu, M., Finnefrock, A. C., Bramhill, D., Cook, J., Eckert, D. M., Hampton, R., Patel, M., Jarantow, S., Joyce, J., Ciliberto, G., Cortese, R., Lu, P., Strohl, W., Schleif, W., McElhaugh, M., Lane, S., Lloyd, C., Lowe, D., Osbourn, J., Vaughan, T., Emini, E., Barbato, G., Kim, P. S., Hazuda, D. J., Shiver, J. W., and Pessi, A. (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc. Natl. Acad. Sci. U.S.A. 102, 14759-14764
39. Luftig, M. A., Mattu, M., Di Giovine, P., Geleziunas, R., Hrin, R., Barbato, G., Bianchi, E., Miller, M. D., Pessi, A., and Carfí, A. (2006) Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat. Struct. Mol. Biol. 13, 740-747
40. Barman, S., and Nayak, D. P. (2007) Lipid raft disruption by cholesterol depletion enhances influenza A virus budding from MDCK cells. J. Virol. 81, 12169-12178
41. Hrin, R., Montgomery, D. L., Wang, F., Condra, J. H., An, Z., Strohl, W. R., Bianchi, E., Pessi, A., Joyce, J. G., and Wang, Y. J. (2008) Short communication: in vitro synergy between peptides or neutralizing antibodies targeting the N- and C-terminal heptad repeats of HIV type 1 gp41. AIDS Res. Hum. Retroviruses 24, 1537-1544
42. Huang, J., Ofek, G., Laub, L., Louder, M. K., Doria-Rose, N. A., Longo, N. S., Imamichi, H., Bailer, R. T., Chakrabarti, B., Sharma, S. K., Alam, S. M., Wang, T., Yang, Y., Zhang, B., Migueles, S. A., Wyatt, R., Haynes, B. F., Kwong, P. D., Mascola, J. R., and Connors, M. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406-412
43. Chen, J., Frey, G., Peng, H., Rits-Volloch, S., Garrity, J., Seaman, M. S., and Chen, B. (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 88, 1249-1258
44. Liu, J., Bartesaghi, A., Borgnia, M. J., Sapiro, G., and Subramaniam, S. (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455, 109-113
45. Zhu, P., Liu, J., Bess, J., Jr., Chertova, E., Lifson, J. D., Grisé, H., Ofek, G. A., Taylor, K. A., and Roux, K. H. (2006) Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847-852
46. Klein, J. S., and Bjorkman, P. J. (2010) Few and far between: how HIV may be evading antibody avidity. PLoS Pathog. 6, e1000908
47. Mouquet, H., Scheid, J. F., Zoller, M. J., Krogsgaard, M., Ott, R. G., Shukair, S., Artyomov, M. N., Pietzsch, J., Connors, M., Pereyra, F., Walker, B. D., Ho, D. D., Wilson, P. C., Seaman, M. S., Eisen, H. N., Chakraborty, A. K., Hope, T. J., Ravetch, J. V., Wardemann, H., and Nussenzweig, M. C. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467, 591-595
48. Rudicell, R. S., Kwon, Y. D., Ko, S.-Y., Pegu, A., Louder, M. K., Georgiev, I. S., Wu, X., Zhu, J., Boyington, J. C., Chen, X., Shi, W., Yang, Z.-Y., Doria-Rose, N. A., McKee, K., O'Dell, S., Schmidt, S. D., Chuang, G.-Y., Druz, A., Soto, C., Yang, Y., Zhang, B., Zhou, T., Todd, J.-P., Lloyd, K. E., Eudailey, J., Roberts, K. E., Donald, B. R., Bailer, R. T., Ledgerwood, J., NISC Comparative Sequencing Program, Mullikin, J. C., Shapiro, L., Koup, R. A., Graham, B. S., Nason, M. C., Connors, M., Haynes, B. F., Rao, S. S., Roederer, M., Kwong, P. D., Mascola, J. R., and Nabel, G. J. (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669-12682
49. Montgomery, D. L., Wang, Y. J., Hrin, R., Luftig, M., Su, B., Miller, M. D., Wang, F., Haytko, P., Huang, L., Vitelli, S., Condra, J., Liu, X., Hampton, R., Carfi, A., Pessi, A., Bianchi, E., Joyce, J., Lloyd, C., Geleziunas, R., Bramhill, D., King, V. M., Finnefrock, A. C., Strohl, W., and An, Z. (2009) Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41. MAbs 1, 462-474
50. Zolot, R. S., Basu, S., and Million, R. P. (2013) Antibody-drug conjugates. Nat. Rev. Drug Discov. 12, 259-260
51. Lingwood, D., and Simons, K. (2010) Lipid rafts as a membrane-organizing principle. Science 327, 46-50
52. Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., Veneziano, M., Bonelli, F., Zhu, L., Monteagudo, E., Marsh, D. J., Sinharoy, R., Bianchi, E., and Pessi, A. (2011) DPP-IV-resistant, long-acting oxyntomodulin derivatives. J. Pept. Sci. 17, 270-280
53. Brown, R. J., Peters, P. J., Caron, C., Gonzalez-Perez, M. P., Stones, L., Ankghuambom, C., Pondei, K., McClure, C. P., Alemnji, G., Taylor, S., Sharp, P. M., Clapham, P. R., and Ball, J. K. (2011) Intercompartmental recombination of HIV-1 contributes to env intrahost diversity and modulates viral tropism and sensitivity to entry inhibitors. J. Virol. 85, 6024-6037